Search

Your search keyword '"Rakisheva, Amina"' showing total 150 results
Start Over Author "Rakisheva, Amina"
150 results on '"Rakisheva, Amina"'

3. Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

Author

Adamopoulos, Stamatis, primary, Bonios, Michael, additional, Ben Gal, Tuvia, additional, Gustafsson, Finn, additional, Abdelhamid, Magdy, additional, Adamo, Marianna, additional, Bayes‐Genis, Antonio, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Cohen‐Solal, Alain, additional, Damman, Kevin, additional, Di Nora, Concetta, additional, Hashmani, Shahrukh, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jankowska, Ewa, additional, Lopatin, Yury, additional, Masetti, Marco, additional, Mehra, Mandeep R., additional, Milicic, Davor, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Nalbantgil, Sanem, additional, Panagiotou, Chrysoula, additional, Piepoli, Massimo, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Rivinius, Rasmus, additional, Savarese, Gianluigi, additional, Thum, Thomas, additional, Tocchetti, Carlo Gabriele, additional, Tops, Laurens F., additional, Van Laake, Linda W., additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Coats, Andrew, additional, Metra, Marco, additional, and Rosano, Giuseppe, additional

Published
2024
Full Text
View/download PDF

4. Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology.

Author

Sliwa, Karen, Rakisheva, Amina, Viljoen, Charle, Pfeffer, Tobias, Simpson, Maggie, Jackson, Alice M., Petrie, Mark C., van der Meer, Peter, Al Farhan, Hasan, Jovanova, Silvana, Mbakwem, Amam, Sinagra, Gianfranco, Van Craenenbroeck, Emeline, Hoevelmann, Julian, Johnson, Mark R., Mindham, Richard, Chioncel, Ovidiu, Kahl, Kai G., Rosano, Giuseppe, and Tschöpe, Carsten

Subjects
*CARDIOVASCULAR nurses, *SOCIAL workers, *HEART failure, *EXTENDED families, *QUALITY of life
Abstract

This statement focuses on the fact that women with peripartum cardiomyopathy (PPCM) have a substantial mortality and morbidity rate. Less than 50% of patients have full recovery of their cardiac function within 6 months of diagnosis. Also, patients with recovered cardiac function often suffer from comorbidities, such as hypertension or arrhythmias, which require long‐term treatment. This has major implications which extend beyond the life of the patient, as it may also substantially impact her family. Women with a new diagnosis of PPCM should be involved in the decision‐making processes regarding therapies, e.g. the recommendation to abstain from breastfeeding, or the use of cardiac implantable electronic devices. Women living with PPCM face the uncertainty of not knowing for some time whether their cardiac function will recover to allow them a near‐to‐normal life expectancy. This not only impacts their ability to work, which may have financial implications, but may also affect mental health and quality of life for the extended family. Women living with PPCM must be informed that a future pregnancy always carries a substantial risk and, in case of poor cardiac recovery, is associated with a high morbidity and mortality. Patients with PPCM are best managed by an interdisciplinary and multiprofessional approach including e.g. a cardiologist, a gynaecologist, nurses, a psychologist, and social workers. The scope of this document encompasses contemporary challenges and approaches for the management of women diagnosed with PPCM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology.

Author

Keramida, Kalliopi, Farmakis, Dimitrios, Rakisheva, Amina, Tocchetti, Carlo Gabriele, Ameri, Pietro, Asteggiano, Riccardo, Barac, Ana, Bax, Jeroen, Bayes‐Genis, Antoni, Bergler Klein, Jutta, Bucciarelli‐Ducci, Chiara, Celutkiene, Jelena, Coats, Andrew J.S., Cohen Solal, Alain, Dent, Susan, Filippatos, Gerasimos, Ghosh, Arjun, Hermann, Joerg, Koop, Yvonne, and Lenihan, Daniel

Subjects
GLOBAL longitudinal strain, CARDIAC amyloidosis, HEART failure, SINGLE-photon emission computed tomography, LOW-molecular-weight heparin, RIGHT ventricular dysfunction, SPECKLE tracking echocardiography
Published
2024
Full Text
View/download PDF

6. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC

Author

Rosano, Giuseppe M.C., primary, Stolfo, Davide, additional, Anderson, Lisa, additional, Abdelhamid, Magdy, additional, Adamo, Marianna, additional, Bauersachs, Johann, additional, Bayes‐Genis, Antoni, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Filippatos, Gerasimos, additional, Hill, Loreena, additional, Lainscak, Mitja, additional, Lambrinou, Ekaterini, additional, Maas, Angela H.E.M., additional, Massouh, Angela R., additional, Moura, Brenda, additional, Petrie, Mark C., additional, Rakisheva, Amina, additional, Ray, Robin, additional, Savarese, Gianluigi, additional, Skouri, Hadi, additional, Van Linthout, Sophie, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Metra, Marco, additional, and Coats, Andrew J.S., additional

Published
2024
Full Text
View/download PDF

7. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC

Author

Savarese, Gianluigi, primary, Lindberg, Felix, additional, Cannata, Antonio, additional, Chioncel, Ovidiu, additional, Stolfo, Davide, additional, Musella, Francesca, additional, Tomasoni, Daniela, additional, Abdelhamid, Magdy, additional, Banerjee, Debasish, additional, Bayes‐Genis, Antoni, additional, Berthelot, Emmanuelle, additional, Braunschweig, Frieder, additional, Coats, Andrew J.S., additional, Girerd, Nicolas, additional, Jankowska, Ewa A., additional, Hill, Loreena, additional, Lainscak, Mitja, additional, Lopatin, Yury, additional, Lund, Lars H., additional, Maggioni, Aldo P., additional, Moura, Brenda, additional, Rakisheva, Amina, additional, Ray, Robin, additional, Seferovic, Petar M., additional, Skouri, Hadi, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Metra, Marco, additional, and Rosano, Giuseppe M.C., additional

Published
2024
Full Text
View/download PDF

8. Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC

Author

Rakisheva, Amina, primary, Sliwa, Karen, additional, Bauersachs, Johann, additional, Van Linthout, Sophie, additional, Chopra, Vijay K., additional, Bayes‐Genis, Antoni, additional, Fruzzetti, Franca, additional, Cannatà, Antonio, additional, Deniau, Benjamin, additional, Mebazaa, Alexandre, additional, Savarese, Gianluigi, additional, Ray, Robin, additional, Vitale, Cristiana, additional, Metra, Marco, additional, and Rosano, Giuseppe M.C., additional

Published
2024
Full Text
View/download PDF

9. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Author

McDonagh, Theresa A., Metra, Marco, Adamo, Marianna, Gardner, Roy S., Baumbach, Andreas, Boehm, Michael, Burri, Haran, Butler, Javed, Celutkiene, Jelena, Chioncel, Ovidiu, Cleland, John G. F., Crespo-Leiro, Maria Generosa, Farmakis, Dimitrios, Gilard, Martine, Heymans, Stephane, Hoes, Arno W., Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lam, Carolyn S. P., Lyon, Alexander R., McMurray, John J. V., Mebazaa, Alexandre, Mindham, Richard, Muneretto, Claudio, Francesco Piepoli, Massimo, Price, Susanna, Rosano, Giuseppe M. C., Ruschitzka, Frank, Skibelund, Anne Kathrine, de Boer, Rudolf A., Schulze, P. Christian, Arbelo, Elena, Bartunek, Jozef, Bauersachs, Johann, Borger, Michael A., Buccheri, Sergio, Cerbai, Elisabetta, Donal, Erwan, Edelmann, Frank, Faerber, Gloria, Heidecker, Bettina, Ibanez, Borja, James, Stefan, Kober, Lars, Koskinas, Konstantinos C., Masip, Josep, McEvoy, John William, Mentz, Robert, Mihaylova, Borislava, Moller, Jacob Eifer, Mullens, Wilfried, Neubeck, Lis, Nielsen, Jens Cosedis, Pasquet, Agnes A., Ponikowski, Piotr, Prescott, Eva, Rakisheva, Amina, Rocca, Bianca, Rossello, Xavier, Sade, Leyla Elif, Schaubroeck, Hannah, Tessitore, Elena, Tokmakova, Mariya, van der Meer, Peter, Van Gelder, Isabelle C., Van Heetvelde, Mattias, Vrints, Christiaan, Wilhelm, Matthias, Witkowski, Adam, Zeppenfeld, Katja, McDonagh, Theresa A., Metra, Marco, Adamo, Marianna, Gardner, Roy S., Baumbach, Andreas, Boehm, Michael, Burri, Haran, Butler, Javed, Celutkiene, Jelena, Chioncel, Ovidiu, Cleland, John G. F., Crespo-Leiro, Maria Generosa, Farmakis, Dimitrios, Gilard, Martine, Heymans, Stephane, Hoes, Arno W., Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lam, Carolyn S. P., Lyon, Alexander R., McMurray, John J. V., Mebazaa, Alexandre, Mindham, Richard, Muneretto, Claudio, Francesco Piepoli, Massimo, Price, Susanna, Rosano, Giuseppe M. C., Ruschitzka, Frank, Skibelund, Anne Kathrine, de Boer, Rudolf A., Schulze, P. Christian, Arbelo, Elena, Bartunek, Jozef, Bauersachs, Johann, Borger, Michael A., Buccheri, Sergio, Cerbai, Elisabetta, Donal, Erwan, Edelmann, Frank, Faerber, Gloria, Heidecker, Bettina, Ibanez, Borja, James, Stefan, Kober, Lars, Koskinas, Konstantinos C., Masip, Josep, McEvoy, John William, Mentz, Robert, Mihaylova, Borislava, Moller, Jacob Eifer, Mullens, Wilfried, Neubeck, Lis, Nielsen, Jens Cosedis, Pasquet, Agnes A., Ponikowski, Piotr, Prescott, Eva, Rakisheva, Amina, Rocca, Bianca, Rossello, Xavier, Sade, Leyla Elif, Schaubroeck, Hannah, Tessitore, Elena, Tokmakova, Mariya, van der Meer, Peter, Van Gelder, Isabelle C., Van Heetvelde, Mattias, Vrints, Christiaan, Wilhelm, Matthias, Witkowski, Adam, and Zeppenfeld, Katja

Abstract

Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Elisabetta Cerbai (Italy), Erwan Donal (France), Frank Edelmann (Germany), Gloria Farber (Germany), Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James (Sweden), Lars Kober (Denmark), Konstantinos C. Koskinas (Switzerland), Josep Masip (Spain), John William McEvoy (Ireland), Robert Mentz (United States of America), Borislava Mihaylova (United Kingdom), Jacob Eifer Moller (Denmark), Wilfried Mullens (Belgium), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Piotr Ponikowski (Poland), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Leyla Elif Sade (United States of America/Turkiye), Hannah Schaubroeck (Belgium), Elena Tessitore (Switzerland), Mariya Tokmakova (Bulgaria), Peter van der Meer (Netherlands), Isabelle C. Van Gelder (Netherlands), Mattias Van Heetvelde (Belgium), Christiaan Vrints (Belgium), Matthias Wilhelm (Switzerland), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands)All experts involved in the development of this Focused Update have submitted declarations of interest. These have been compiled in a report and simultaneously published in a supplementary document to the Focused Update. The report is also available on the ESC websiteSee the European Heart Journal online for supplementary documents that include evidence tables.

Published
2024
Full Text
View/download PDF

10. Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT

Author

Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D., Bayes-Genis, Antonio, Gal, Tuvia Ben, Bowen, T. Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavaretta, Elena, Chioncel, Ovidiu, Coats, Andrew J. S., Cohen-Solal, Alain, D'Ascenzi, Flavio, Zarzosa, Carmen de Pablo, Gevaert, Andreas B., Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H., Moura, Brenda, Nytroen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M., Thompson, David R., Thum, Thomas, Van Craenenbroeck, Emeline M., Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D., Bayes-Genis, Antonio, Gal, Tuvia Ben, Bowen, T. Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavaretta, Elena, Chioncel, Ovidiu, Coats, Andrew J. S., Cohen-Solal, Alain, D'Ascenzi, Flavio, Zarzosa, Carmen de Pablo, Gevaert, Andreas B., Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H., Moura, Brenda, Nytroen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M., Thompson, David R., Thum, Thomas, and Van Craenenbroeck, Emeline M.

Abstract

Little is known either about either physical activity patterns, or other lifestyle-related prevention measures in heart transplantation (HTx) recipients. The history of HTx started more than 50 years ago but there are still no guidelines or position papers highlighting the features of prevention and rehabilitation after HTx. The aims of this scientific statement are (i) to explain the importance of prevention and rehabilitation after HTx, and (ii) to promote the factors (modifiable/non-modifiable) that should be addressed after HTx to improve patients' physical capacity, quality of life and survival. All HTx team members have their role to play in the care of these patients and multidisciplinary prevention and rehabilitation programmes designed for transplant recipients. HTx recipients are clearly not healthy disease-free subjects yet they also significantly differ from heart failure patients or those who are supported with mechanical circulatory support. Therefore, prevention and rehabilitation after HTx both need to be specifically tailored to this patient population and be multidisciplinary in nature. Prevention and rehabilitation programmes should be initiated early after HTx and continued during the entire post-transplant journey. This clinical consensus, Funding Agencies|European Journal of Heart Failure; Transplant International

Published
2024
Full Text
View/download PDF

11. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)

Author

Team Medisch, Circulatory Health, Verplegingswetenschap, Mullens, Wilfried, Dauw, Jeroen, Gustafsson, Finn, Mebazaa, Alexandre, Steffel, Jan, Witte, Klaus K., Delgado, Victoria, Linde, Cecilia, Vernooy, Kevin, Anker, Stefan D., Chioncel, Ovidiu, Milicic, Davor, Hasenfuß, Gerd, Ponikowski, Piotr, von Bardeleben, Ralph Stephan, Koehler, Friedrich, Ruschitzka, Frank, Damman, Kevin, Schwammenthal, Ehud, Testani, Jeffrey M., Zannad, Faiez, Böhm, Michael, Cowie, Martin R., Dickstein, Kenneth, Jaarsma, Tiny, Filippatos, Gerasimos, Volterrani, Maurizio, Thum, Thomas, Adamopoulos, Stamatis, Cohen-Solal, Alain, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antoni, Van Linthout, Sophie, Tocchetti, Carlo Gabriele, Savarese, Gianluigi, Skouri, Hadi, Adamo, Marianna, Amir, Offer, Yilmaz, Mehmet Birhan, Simpson, Maggie, Tokmakova, Mariya, González, Arantxa, Piepoli, Massimo, Seferovic, Petar, Metra, Marco, Coats, Andrew J.S., Rosano, Giuseppe M.C., Team Medisch, Circulatory Health, Verplegingswetenschap, Mullens, Wilfried, Dauw, Jeroen, Gustafsson, Finn, Mebazaa, Alexandre, Steffel, Jan, Witte, Klaus K., Delgado, Victoria, Linde, Cecilia, Vernooy, Kevin, Anker, Stefan D., Chioncel, Ovidiu, Milicic, Davor, Hasenfuß, Gerd, Ponikowski, Piotr, von Bardeleben, Ralph Stephan, Koehler, Friedrich, Ruschitzka, Frank, Damman, Kevin, Schwammenthal, Ehud, Testani, Jeffrey M., Zannad, Faiez, Böhm, Michael, Cowie, Martin R., Dickstein, Kenneth, Jaarsma, Tiny, Filippatos, Gerasimos, Volterrani, Maurizio, Thum, Thomas, Adamopoulos, Stamatis, Cohen-Solal, Alain, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antoni, Van Linthout, Sophie, Tocchetti, Carlo Gabriele, Savarese, Gianluigi, Skouri, Hadi, Adamo, Marianna, Amir, Offer, Yilmaz, Mehmet Birhan, Simpson, Maggie, Tokmakova, Mariya, González, Arantxa, Piepoli, Massimo, Seferovic, Petar, Metra, Marco, Coats, Andrew J.S., and Rosano, Giuseppe M.C.

Published
2024

12. Prevention and Rehabilitation After Heart Transplantation: A Clinical Consensus Statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a Section of ESOT

Author

Circulatory Health, Verplegingswetenschap, Healthcare Innovation & Evaluation, Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D., Bayes-Genis, Antonio, Ben Gal, Tuvia, Bowen, T. Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavarretta, Elena, Chioncel, Ovidiu, Coats, Andrew J.S., Cohen-Solal, Alain, D’Ascenzi, Flavio, de Pablo Zarzosa, Carmen, Gevaert, Andreas B., Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H., Moura, Brenda, Nytrøen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M., Thompson, David R., Thum, Thomas, Van Craenenbroeck, Emeline M., Circulatory Health, Verplegingswetenschap, Healthcare Innovation & Evaluation, Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D., Bayes-Genis, Antonio, Ben Gal, Tuvia, Bowen, T. Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavarretta, Elena, Chioncel, Ovidiu, Coats, Andrew J.S., Cohen-Solal, Alain, D’Ascenzi, Flavio, de Pablo Zarzosa, Carmen, Gevaert, Andreas B., Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H., Moura, Brenda, Nytrøen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M., Thompson, David R., Thum, Thomas, and Van Craenenbroeck, Emeline M.

Published
2024

13. Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT

Author

Team Medisch, Circulatory Health, Verplegingswetenschap, Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D., Bayes-Genis, Antonio, Gal, Tuvia Ben, Bowen, T. Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavarretta, Elena, Chioncel, Ovidiu, Coats, Andrew J.S., Cohen-Solal, Alain, D’Ascenzi, Flavio, de Pablo Zarzosa, Carmen, Gevaert, Andreas B., Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H., Moura, Brenda, Nytrøen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M., Thompson, David R., Thum, Thomas, Van Craenenbroeck, Emeline M., Team Medisch, Circulatory Health, Verplegingswetenschap, Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D., Bayes-Genis, Antonio, Gal, Tuvia Ben, Bowen, T. Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavarretta, Elena, Chioncel, Ovidiu, Coats, Andrew J.S., Cohen-Solal, Alain, D’Ascenzi, Flavio, de Pablo Zarzosa, Carmen, Gevaert, Andreas B., Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H., Moura, Brenda, Nytrøen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M., Thompson, David R., Thum, Thomas, and Van Craenenbroeck, Emeline M.

Published
2024

14. Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

Author

Adamopoulos, Stamatis, Bonios, Michael, Ben Gal, Tuvia, Gustafsson, Finn, Abdelhamid, Magdy, Adamo, Marianna, Bayes-Genis, Antonio, Boehm, Michael, Chioncel, Ovidiu, Cohen-Solal, Alain, Damman, Kevin, Di Nora, Concetta, Hashmani, Shahrukh, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Lopatin, Yury, Masetti, Marco, Mehra, Mandeep R., Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Nalbantgil, Sanem, Panagiotou, Chrysoula, Piepoli, Massimo, Rakisheva, Amina, Ristic, Arsen, Rivinius, Rasmus, Savarese, Gianluigi, Thum, Thomas, Tocchetti, Carlo Gabriele, Tops, Laurens F., Van Laake, Linda W., Volterrani, Maurizio, Seferovic, Petar, Coats, Andrew, Metra, Marco, Rosano, Giuseppe, Adamopoulos, Stamatis, Bonios, Michael, Ben Gal, Tuvia, Gustafsson, Finn, Abdelhamid, Magdy, Adamo, Marianna, Bayes-Genis, Antonio, Boehm, Michael, Chioncel, Ovidiu, Cohen-Solal, Alain, Damman, Kevin, Di Nora, Concetta, Hashmani, Shahrukh, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Lopatin, Yury, Masetti, Marco, Mehra, Mandeep R., Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Nalbantgil, Sanem, Panagiotou, Chrysoula, Piepoli, Massimo, Rakisheva, Amina, Ristic, Arsen, Rivinius, Rasmus, Savarese, Gianluigi, Thum, Thomas, Tocchetti, Carlo Gabriele, Tops, Laurens F., Van Laake, Linda W., Volterrani, Maurizio, Seferovic, Petar, Coats, Andrew, Metra, Marco, and Rosano, Giuseppe

Abstract

Right heart failure (RHF) following implantation of a left ventricular assist device (LVAD) is a common and potentially serious condition with a wide spectrum of clinical presentations with an unfavourable effect on patient outcomes. Clinical scores that predict the occurrence of right ventricular (RV) failure have included multiple clinical, biochemical, imaging and haemodynamic parameters. However, unless the right ventricle is overtly dysfunctional with end-organ involvement, prediction of RHF post-LVAD implantation is, in most cases, difficult and inaccurate. For these reasons optimization of RV function in every patient is a reasonable practice aiming at preparing the right ventricle for a new and challenging haemodynamic environment after LVAD implantation. To this end, the institution of diuretics, inotropes and even temporary mechanical circulatory support may improve RV function, thereby preparing it for a better adaptation post-LVAD implantation. Furthermore, meticulous management of patients during the perioperative and immediate postoperative period should facilitate identification of RV failure refractory to medication. When RHF occurs late during chronic LVAD support, this is associated with worse long-term outcomes. Careful monitoring of RV function and characterization of the origination deficit should therefore continue throughout the patient's entire follow-up. Despite the useful information provided by the echocardiogram with respect to RV function, right heart catheterization frequently offers additional support for the assessment and optimization of RV function in LVAD-supported patients. In any patient candidate for LVAD therapy, evaluation and treatment of RV function and failure should be assessed in a multidimensional and multidisciplinary manner.

Published
2024
Full Text
View/download PDF

15. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)

Author

Mullens, Wilfried, Dauw, Jeroen, Gustafsson, Finn, Mebazaa, Alexandre, Steffel, Jan, Witte, Klaus K., Delgado, Victoria, Linde, Cecilia, Vernooy, Kevin, Anker, Stefan D., Chioncel, Ovidiu, Milicic, Davor, Hasenfuss, Gerd, Ponikowski, Piotr, Stephan von Bardeleben, Ralph, Koehler, Friedrich, Ruschitzka, Frank, Damman, Kevin, Schwammenthal, Ehud, Testani, Jeffrey M., Zannad, Faiez, Boehm, Michael, Cowie, Martin R., Dickstein, Kenneth, Jaarsma, Tiny, Filippatos, Gerasimos, Volterrani, Maurizio, Thum, Thomas, Adamopoulos, Stamatis, Cohen-Solal, Alain, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antoni, Van Linthout, Sophie, Tocchetti, Carlo Gabriele, Savarese, Gianluigi, Skouri, Hadi, Adamo, Marianna, Amir, Offer, Yilmaz, Mehmet Birhan, Simpson, Maggie, Tokmakova, Mariya, Gonzalez, Arantxa, Piepoli, Massimo, Seferovic, Petar, Metra, Marco, Coats, Andrew J. S., Rosano, Giuseppe M. C., Mullens, Wilfried, Dauw, Jeroen, Gustafsson, Finn, Mebazaa, Alexandre, Steffel, Jan, Witte, Klaus K., Delgado, Victoria, Linde, Cecilia, Vernooy, Kevin, Anker, Stefan D., Chioncel, Ovidiu, Milicic, Davor, Hasenfuss, Gerd, Ponikowski, Piotr, Stephan von Bardeleben, Ralph, Koehler, Friedrich, Ruschitzka, Frank, Damman, Kevin, Schwammenthal, Ehud, Testani, Jeffrey M., Zannad, Faiez, Boehm, Michael, Cowie, Martin R., Dickstein, Kenneth, Jaarsma, Tiny, Filippatos, Gerasimos, Volterrani, Maurizio, Thum, Thomas, Adamopoulos, Stamatis, Cohen-Solal, Alain, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antoni, Van Linthout, Sophie, Tocchetti, Carlo Gabriele, Savarese, Gianluigi, Skouri, Hadi, Adamo, Marianna, Amir, Offer, Yilmaz, Mehmet Birhan, Simpson, Maggie, Tokmakova, Mariya, Gonzalez, Arantxa, Piepoli, Massimo, Seferovic, Petar, Metra, Marco, Coats, Andrew J. S., and Rosano, Giuseppe M. C.

Abstract

Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support. For others, more evidence is still needed before large-scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device-provided therapy and also device-guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care.

Published
2024
Full Text
View/download PDF

16. Management of cardiac emergencies in women. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the European Heart Rhythm Association (EHRA) of the ESC, and the ESC Working Group on Cardiovascular Pharmacotherapy

Author

Sambola, Antonia, primary, Halvorsen, Sigrun, additional, Adlam, David, additional, Hassager, Christian, additional, Price, Susanna, additional, Rosano, Giuseppe, additional, Schiele, Francois, additional, Holmvang, Lene, additional, de Riva, Marta, additional, Rakisheva, Amina, additional, Sulzgruber, Patrick, additional, and Swahn, Eva, additional

Published
2024
Full Text
View/download PDF

19. European Society of Cardiology Core Curriculum for Cardio‐Oncology

Author

López‐Fernández, Teresa, primary, Farmakis, Dimitrios, additional, Ameri, Pietro, additional, Asteggiano, Riccardo, additional, de Azambuja, Evandro, additional, Aznar, Marianne, additional, Barac, Ana, additional, Bayes‐Genis, Antoni, additional, Bax, Jeroen J., additional, Bergler‐Klein, Jutta, additional, Boriani, Giuseppe, additional, Celutkiene, Jelena, additional, Coats, Andrew, additional, Cohen‐Solal, Alain, additional, Córdoba, Raúl, additional, Cosyns, Bernard, additional, Filippatos, Gerasimos, additional, Fox, Kevin, additional, Gulati, Geeta, additional, Inciardi, Riccardo M., additional, Lee, Geraldine, additional, Mamas, Mamas A., additional, Novo, Giuseppina, additional, Plummer, Chris, additional, Psyrri, Amanda, additional, Rakisheva, Amina, additional, Suter, Thomas, additional, Tini, Giacomo, additional, Tocchetti, Carlo Gabriele, additional, Toutouzas, Konstantinos, additional, Wilhelm, Matthias, additional, Metra, Marco, additional, Lyon, Alexander R., additional, and Rosano, Giuseppe M. C., additional

Published
2023
Full Text
View/download PDF

20. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program

Author

Lopatin, Yuri M., Cowie, Martin R., Grebennikova, Anna A., Sisakian, Hamayak S., Pagava, Zurab M., Hayrapetyan, Hamlet G., Abdullaev, Timur A., Voronkov, Leonid G., Chesnikova, Anna I., Tseluyko, Vira I., Tarlovskaya, Ekaterina I., Dadashova, Gülnaz M., Berkinbaev, Salim F., Glezer, Maria G., Koziolova, Natalia A., Rakisheva, Amina G., Kipiani, Zviad V., and Kurlyanskaya, Alena K.

Published
2018
Full Text
View/download PDF

22. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

Author

Anker, Stefan D., primary, Usman, Muhammad Shariq, additional, Anker, Markus S., additional, Butler, Javed, additional, Böhm, Michael, additional, Abraham, William T., additional, Adamo, Marianna, additional, Chopra, Vijay K., additional, Cicoira, Mariantonietta, additional, Cosentino, Francesco, additional, Filippatos, Gerasimos, additional, Jankowska, Ewa A., additional, Lund, Lars H., additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Pieske, Burkert, additional, Ponikowski, Piotr, additional, Gonzalez‐Juanatey, Jose R., additional, Rakisheva, Amina, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Teerlink, John R., additional, Tschöpe, Carsten, additional, Volterrani, Maurizio, additional, von Haehling, Stephan, additional, Zhang, Jian, additional, Zhang, Yuhui, additional, Bauersachs, Johann, additional, Landmesser, Ulf, additional, Zieroth, Shelley, additional, Tsioufis, Konstantinos, additional, Bayes‐Genis, Antoni, additional, Chioncel, Ovidiu, additional, Andreotti, Felicita, additional, Agabiti‐Rosei, Enrico, additional, Merino, Jose L., additional, Metra, Marco, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2023
Full Text
View/download PDF

23. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology

Author

Chioncel, Ovidiu, primary, Adamo, Marianna, additional, Nikolaou, Maria, additional, Parissis, John, additional, Mebazaa, Alexandre, additional, Yilmaz, Mehmet Birhan, additional, Hassager, Christian, additional, Moura, Brenda, additional, Bauersachs, Johann, additional, Harjola, Veli‐Pekka, additional, Antohi, Elena‐Laura, additional, Ben‐Gal, Tuvia, additional, Collins, Sean P., additional, Iliescu, Vlad Anton, additional, Abdelhamid, Magdy, additional, Čelutkienė, Jelena, additional, Adamopoulos, Stamatis, additional, Lund, Lars H., additional, Cicoira, Mariantonietta, additional, Masip, Josep, additional, Skouri, Hadi, additional, Gustafsson, Finn, additional, Rakisheva, Amina, additional, Ahrens, Ingo, additional, Mortara, Andrea, additional, Janowska, Ewa A., additional, Almaghraby, Abdallah, additional, Damman, Kevin, additional, Miro, Oscar, additional, Huber, Kurt, additional, Ristic, Arsen, additional, Hill, Loreena, additional, Mullens, Wilfried, additional, Chieffo, Alaide, additional, Bartunek, Jozef, additional, Paolisso, Pasquale, additional, Bayes‐Genis, Antoni, additional, Anker, Stefan D., additional, Price, Susanna, additional, Filippatos, Gerasimos, additional, Ruschitzka, Frank, additional, Seferovic, Petar, additional, Vidal‐Perez, Rafael, additional, Vahanian, Alec, additional, Metra, Marco, additional, McDonagh, Theresa A., additional, Barbato, Emanuele, additional, Coats, Andrew J.S., additional, and Rosano, Giuseppe M.C., additional

Published
2023
Full Text
View/download PDF

24. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology

Author

Metra, Marco, Tomasoni, Daniela, Adamo, Marianna, Bayes-Genis, Antoni, Filippatos, Gerasimos, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Antohi, Laura, Böhm, Michael, Braunschweig, Frieder, Gal, Tuvia Ben, Butler, Javed, Cleland, John G F, Cohen-Solal, Alain, Damman, Kevin, Gustafsson, Finn, Hill, Loreena, Jankowska, Ewa A, Lainscak, Mitja, Lund, Lars H, McDonagh, Theresa, Mebazaa, Alexandre, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Tocchetti, Carlo Gabriele, Yılmaz, Mehmet Birhan, Vitale, Cristiana, Volterrani, Maurizio, von Haehling, Stephan, Chioncel, Ovidiu, Coats, Andrew J S, Rosano, Giuseppe, Metra, Marco, Tomasoni, Daniela, Adamo, Marianna, Bayes-Genis, Antoni, Filippatos, Gerasimo, Abdelhamid, Magdy, Adamopoulos, Stamati, Anker, Stefan D, Antohi, Laura, Böhm, Michael, Braunschweig, Frieder, Gal, Tuvia Ben, Butler, Javed, Cleland, John G F, Cohen-Solal, Alain, Damman, Kevin, Gustafsson, Finn, Hill, Loreena, Jankowska, Ewa A, Lainscak, Mitja, Lund, Lars H, Mcdonagh, Theresa, Mebazaa, Alexandre, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Tocchetti, Carlo Gabriele, Yılmaz, Mehmet Birhan, Vitale, Cristiana, Volterrani, Maurizio, von Haehling, Stephan, Chioncel, Ovidiu, Coats, Andrew J S, and Rosano, Giuseppe

Subjects
Hospitalization, Emergency department visits, Intensification of oral therapy, Outpatients, Prognosis, Worsening heart failure, Prognosi, Outpatient, Emergency department visit, Cardiology and Cardiovascular Medicine
Abstract

Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention of first and recurring episodes of worsening HF is an essential component of HF treatment and this may be achieved through early and rapid administration of GRMT. The aim of the present clinical consensus statement by the Heart Failure Association of the European Society of Cardiology is to provide an update on the definition, clinical characteristics, management and prevention of worsening HF in clinical practice.

Published
2023

25. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC

Author

Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Bauersachs, Johann, Belenkov, Yuri, Boehm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, Rosano, Giuseppe, Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Bauersachs, Johann, Belenkov, Yuri, Boehm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, and Rosano, Giuseppe

Abstract

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure.

Published
2023
Full Text
View/download PDF

26. Acute heart failure and valvular heart disease:A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology

Author

Chioncel, Ovidiu, Adamo, Marianna, Nikolaou, Maria, Parissis, John, Mebazaa, Alexandre, Yilmaz, Mehmet Birhan, Hassager, Christian, Moura, Brenda, Bauersachs, Johann, Harjola, Veli Pekka, Antohi, Elena Laura, Ben-Gal, Tuvia, Collins, Sean P., Iliescu, Vlad Anton, Abdelhamid, Magdy, Čelutkienė, Jelena, Adamopoulos, Stamatis, Lund, Lars H., Cicoira, Mariantonietta, Masip, Josep, Skouri, Hadi, Gustafsson, Finn, Rakisheva, Amina, Ahrens, Ingo, Mortara, Andrea, Janowska, Ewa A., Almaghraby, Abdallah, Damman, Kevin, Miro, Oscar, Huber, Kurt, Ristic, Arsen, Hill, Loreena, Mullens, Wilfried, Chieffo, Alaide, Bartunek, Jozef, Paolisso, Pasquale, Bayes-Genis, Antoni, Anker, Stefan D., Price, Susanna, Filippatos, Gerasimos, Ruschitzka, Frank, Seferovic, Petar, Vidal-Perez, Rafael, Vahanian, Alec, Metra, Marco, McDonagh, Theresa A., Barbato, Emanuele, Coats, Andrew J.S., Rosano, Giuseppe M.C., Chioncel, Ovidiu, Adamo, Marianna, Nikolaou, Maria, Parissis, John, Mebazaa, Alexandre, Yilmaz, Mehmet Birhan, Hassager, Christian, Moura, Brenda, Bauersachs, Johann, Harjola, Veli Pekka, Antohi, Elena Laura, Ben-Gal, Tuvia, Collins, Sean P., Iliescu, Vlad Anton, Abdelhamid, Magdy, Čelutkienė, Jelena, Adamopoulos, Stamatis, Lund, Lars H., Cicoira, Mariantonietta, Masip, Josep, Skouri, Hadi, Gustafsson, Finn, Rakisheva, Amina, Ahrens, Ingo, Mortara, Andrea, Janowska, Ewa A., Almaghraby, Abdallah, Damman, Kevin, Miro, Oscar, Huber, Kurt, Ristic, Arsen, Hill, Loreena, Mullens, Wilfried, Chieffo, Alaide, Bartunek, Jozef, Paolisso, Pasquale, Bayes-Genis, Antoni, Anker, Stefan D., Price, Susanna, Filippatos, Gerasimos, Ruschitzka, Frank, Seferovic, Petar, Vidal-Perez, Rafael, Vahanian, Alec, Metra, Marco, McDonagh, Theresa A., Barbato, Emanuele, Coats, Andrew J.S., and Rosano, Giuseppe M.C.

Abstract

Acute heart failure (AHF) represents a broad spectrum of disease states, resulting from the interaction between an acute precipitant and a patient's underlying cardiac substrate and comorbidities. Valvular heart disease (VHD) is frequently associated with AHF. AHF may result from several precipitants that add an acute haemodynamic stress superimposed on a chronic valvular lesion or may occur as a consequence of a new significant valvular lesion. Regardless of the mechanism, clinical presentation may vary from acute decompensated heart failure to cardiogenic shock. Assessing the severity of VHD as well as the correlation between VHD severity and symptoms may be difficult in patients with AHF because of the rapid variation in loading conditions, concomitant destabilization of the associated comorbidities and the presence of combined valvular lesions. Evidence-based interventions targeting VHD in settings of AHF have yet to be identified, as patients with severe VHD are often excluded from randomized trials in AHF, so results from these trials do not generalize to those with VHD. Furthermore, there are not rigorously conducted randomized controlled trials in the setting of VHD and AHF, most of the data coming from observational studies. Thus, distinct to chronic settings, current guidelines are very elusive when patients with severe VHD present with AHF, and a clear-cut strategy could not be yet defined. Given the paucity of evidence in this subset of AHF patients, the aim of this scientific statement is to describe the epidemiology, pathophysiology, and overall treatment approach for patients with VHD who present with AHF., Acute heart failure (AHF) represents a broad spectrum of disease states, resulting from the interaction between an acute precipitant and a patient's underlying cardiac substrate and comorbidities. Valvular heart disease (VHD) is frequently associated with AHF. AHF may result from several precipitants that add an acute haemodynamic stress superimposed on a chronic valvular lesion or may occur as a consequence of a new significant valvular lesion. Regardless of the mechanism, clinical presentation may vary from acute decompensated heart failure to cardiogenic shock. Assessing the severity of VHD as well as the correlation between VHD severity and symptoms may be difficult in patients with AHF because of the rapid variation in loading conditions, concomitant destabilization of the associated comorbidities and the presence of combined valvular lesions. Evidence-based interventions targeting VHD in settings of AHF have yet to be identified, as patients with severe VHD are often excluded from randomized trials in AHF, so results from these trials do not generalize to those with VHD. Furthermore, there are not rigorously conducted randomized controlled trials in the setting of VHD and AHF, most of the data coming from observational studies. Thus, distinct to chronic settings, current guidelines are very elusive when patients with severe VHD present with AHF, and a clear-cut strategy could not be yet defined. Given the paucity of evidence in this subset of AHF patients, the aim of this scientific statement is to describe the epidemiology, pathophysiology, and overall treatment approach for patients with VHD who present with AHF.

Published
2023

27. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure:A scientific statement by the Heart Failure Association of the ESC

Author

Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Bauersachs, Johann, Belenkov, Yuri, Böhm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, Rosano, Giuseppe, Metra, Marco, Adamo, Marianna, Tomasoni, Daniela, Mebazaa, Alexandre, Bayes-Genis, Antoni, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Bauersachs, Johann, Belenkov, Yuri, Böhm, Michael, Gal, Tuvia Ben, Butler, Javed, Cohen-Solal, Alain, Filippatos, Gerasimos, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Lainscak, Mitja, Lopatin, Yuri, Lund, Lars H., McDonagh, Theresa, Milicic, Davor, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Polovina, Marija, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Thum, Thomas, Tocchetti, Carlo G., Van Linthout, Sophie, Vitale, Cristiana, Von Haehling, Stephan, Volterrani, Maurizio, Coats, Andrew J. S., Chioncel, Ovidiu, and Rosano, Giuseppe

Abstract

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure., Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked increases in death and rehospitalization rates, which then decline exponentially though they remain higher than in patients without a recent hospitalization. Therefore, optimal management of patients with acute heart failure before discharge and in the early post-discharge phase is critical. First, it may prevent rehospitalizations through the early detection and effective treatment of residual or recurrent congestion, the main manifestation of decompensation. Second, initiation at pre-discharge and titration to target doses in the early post-discharge period, of guideline-directed medical therapy may improve both short- and long-term outcomes. Third, in chronic heart failure, medical treatment is often left unchanged, so the acute heart failure hospitalization presents an opportunity for implementation of therapy. The aim of this scientific statement by the Heart Failure Association of the European Society of Cardiology is to summarize recent findings that have implications for clinical management both in the pre-discharge and the early post-discharge phase after a hospitalization for acute heart failure.

Published
2023

28. Worsening of chronic heart failure:definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology

Author

Metra, Marco, Tomasoni, Daniela, Adamo, Marianna, Bayes-Genis, Antoni, Filippatos, Gerasimos, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Antohi, Laura, Böhm, Michael, Braunschweig, Frieder, Gal, Tuvia Ben, Butler, Javed, Cleland, John G.F., Cohen-Solal, Alain, Damman, Kevin, Gustafsson, Finn, Hill, Loreena, Jankowska, Ewa A., Lainscak, Mitja, Lund, Lars H., McDonagh, Theresa, Mebazaa, Alexandre, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Tocchetti, Carlo Gabriele, Yilmaz, Mehmet Birhan, Vitale, Cristiana, Volterrani, Maurizio, von Haehling, Stephan, Chioncel, Ovidiu, Coats, Andrew J.S., Rosano, Giuseppe, Metra, Marco, Tomasoni, Daniela, Adamo, Marianna, Bayes-Genis, Antoni, Filippatos, Gerasimos, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Antohi, Laura, Böhm, Michael, Braunschweig, Frieder, Gal, Tuvia Ben, Butler, Javed, Cleland, John G.F., Cohen-Solal, Alain, Damman, Kevin, Gustafsson, Finn, Hill, Loreena, Jankowska, Ewa A., Lainscak, Mitja, Lund, Lars H., McDonagh, Theresa, Mebazaa, Alexandre, Moura, Brenda, Mullens, Wilfried, Piepoli, Massimo, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Seferovic, Petar, Sharma, Rajan, Tocchetti, Carlo Gabriele, Yilmaz, Mehmet Birhan, Vitale, Cristiana, Volterrani, Maurizio, von Haehling, Stephan, Chioncel, Ovidiu, Coats, Andrew J.S., and Rosano, Giuseppe

Abstract

Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention of first and recurring episodes of worsening HF is an essential component of HF treatment and this may be achieved through early and rapid administration of GRMT. The aim of the present clinical consensus statement by the Heart Failure Association of the European Society of Cardiology is to provide an update on the definition, clinical characteristics, management and prevention of worsening HF in clinical practice., Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention of first and recurring episodes of worsening HF is an essential component of HF treatment and this may be achieved through early and rapid administration of GRMT. The aim of the present clinical consensus statement by the Heart Failure Association of the European Society of Cardiology is to provide an update on the definition, clinical characteristics, management and prevention of worsening HF in clinical practice.

Published
2023

29. Pre‐discharge and early post‐discharge management of patients hospitalized for acute heart failure: a scientific statement by the Heart Failure Association ( HFA ) of the ESC

Author

Metra, Marco, primary, Adamo, Marianna, additional, Tomasoni, Daniela, additional, Mebazaa, Alexandre, additional, Bayes‐Genis, Antoni, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Bauersachs, Johann, additional, Belenkov, Yuri, additional, Böhm, Michael, additional, Gal, Tuvia Ben, additional, Butler, Javed, additional, Cohen‐Solal, Alain, additional, Filippatos, Gerasimos, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jankowska, Ewa A., additional, Lainscak, Mitja, additional, Lopatin, Yuri, additional, Lund, Lars, additional, McDonagh, Theresa, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Piepoli, Massimo, additional, Polovina, Marija, additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Sharma, Rajan, additional, Thum, Thomas, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Vitale, Cristiana, additional, Von Haehling, Stephan, additional, Volterrani, Maurizio, additional, Coats, Andrew JS, additional, Chioncel, Ovidiu, additional, and Rosano, Giuseppe, additional

Published
2023
Full Text
View/download PDF

30. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association ( HFA ) of the ESC

Author

Metra, Marco, primary, Tomasoni, Daniela, additional, Adamo, Marianna, additional, Bayes‐Genis, Antoni, additional, Filippatos, Gerasimos, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Antohi, Laura, additional, Böhm, Michael, additional, Braunschweig, Frieder, additional, Gal, Tuvia Ben, additional, Butler, Javed, additional, Cleland, John G.F., additional, Cohen‐Solal, Alain, additional, Damman, Kevin, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lund, Lars H., additional, McDonagh, Theresa, additional, Mebazaa, Alexandre, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Piepoli, Massimo, additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Sharma, Rajan, additional, Tocchetti, Carlo Gabriele, additional, Yılmaz, Mehmet Birhan, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Von Haehling, Stephan, additional, Chioncel, Ovidiu, additional, Coats, Andrew JS, additional, and Rosano, Giuseppe, additional

Published
2023
Full Text
View/download PDF

31. Cardiac remodelling part 2: clinical, imaging and laboratory findings: a review from the Biomarkers Working Group of the Heart Failure Association of the ESC

Author

Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao‐Pires, Inês, Díez, Javier, Foo, Roger SY, Chan, Mark Yan Yee, Anene‐Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen‐Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew JS, Emdin, Michele, Bayes‐Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thoma, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inê, Díez, Javier, Foo, Roger Sy, Chan, Mark Yan Yee, Anene-Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamati, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J, Emdin, Michele, and Bayes-Genis, Antoni

Subjects
therapies, biomarker, heart failure, imaging, predictor, remodelling, ejection fraction, clinical
Abstract

In patients with heart failure (HF), the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Biomarker Study Group of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with HFrEF because most studies on cardiac remodelling focused on this setting.

Published
2022

33. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology

Author

Chioncel, Ovidiu, Adamo, Marianna, Nikolaou, Maria, Parissis, John, Mebazaa, Alexandre, Yilmaz, Mehmet Birhan, Hassager, Christian, Moura, Brenda, Bauersachs, Johann, Harjola, Veli-Pekka, Antohi, Elena-Laura, Ben-Gal, Tuvia, Collins, Sean P, Iliescu, Vlad Anton, Abdelhamid, Magdy, Čelutkienė, Jelena, Adamopoulos, Stamatis, Lund, Lars H, Cicoira, Mariantonietta, Masip, Josep, Skouri, Hadi, Gustafsson, Finn, Rakisheva, Amina, Ahrens, Ingo, Mortara, Andrea, Janowska, Ewa A, Almaghraby, Abdallah, Damman, Kevin, Miro, Oscar, Huber, Kurt, Ristic, Arsen, Hill, Loreena, Mullens, Wilfried, Chieffo, Alaide, Bartunek, Jozef, Paolisso, Pasquale, Bayes-Genis, Antoni, Anker, Stefan D, Price, Susanna, Filippatos, Gerasimos, Ruschitzka, Frank, Seferovic, Petar, Vidal-Perez, Rafael, Vahanian, Alec, Metra, Marco, Mcdonagh, Theresa A, Barbato, Emanuele, Coats, Andrew J S, and Rosano, Giuseppe M C

Subjects
Acute heart failure, Management, Valvular heart disease
Abstract

Acute heart failure (AHF) represents a broad spectrum of disease states, resulting from the interaction between an acute precipitant and a patient's underlying cardiac substrate and comorbidities. Valvular heart disease (VHD) is frequently associated with AHF. AHF may result from several precipitants that add an acute haemodynamic stress superimposed on a chronic valvular lesion or may occur as a consequence of a new significant valvular lesion. Regardless of the mechanism, clinical presentation may vary from acute decompensated heart failure to cardiogenic shock. Assessing the severity of VHD as well as the correlation between VHD severity and symptoms may be difficult in patients with AHF because of the rapid variation in loading conditions, concomitant destabilization of the associated comorbidities and the presence of combined valvular lesions. Evidence-based interventions targeting VHD in settings of AHF have yet to be identified, as patients with severe VHD are often excluded from randomized trials in AHF, so results from these trials do not generalize to those with VHD. Furthermore, there are not rigorously conducted randomized controlled trials in the setting of VHD and AHF, most of the data coming from observational studies. Thus, distinct to chronic settings, current guidelines are very elusive when patients with severe VHD present with AHF, and a clear-cut strategy could not be yet defined. Given the paucity of evidence in this subset of AHF patients, the aim of this scientific statement is to describe the epidemiology, pathophysiology, and overall treatment approach for patients with VHD who present with AHF.

Published
2023

34. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology

Author

Mullens, Wilfried, Coats, Andrew J.S., Seferović, Petar M., Metra, Marco I., Mebazaa, Alexandre, Ruschitzka, Frank T., Filippatos, Gerasimos S., Volterrani, Maurizio, Ponikowski, Piotr P., Jankowska, Ewa Anita, Chioncel, Ovidiu, McDonagh, Theresa A., Piepoli, Massimo F., Milicic, Davor, Thum, Thomas, Hill, Loreena Michelle, Abdelhamid, Magdy, Adamopoulos, Stamatis, Belenkov, Yuri, Ben-Gal, Tuvia, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen D., Bayes-Genis, Antonio, Van Linthout, Sophia, Anker, Stefan D., Tocchetti, Carlo Gabriele, Lopatin, Yuri, Lund, Lars, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Markus, Rosano, Giuseppe M C, Mullens, Wilfried, Coats, Andrew, Seferovic, Petar, Metra, Marco, Mebazaa, Alexandre, Ruschitzka, Frank, Filippatos, Gerasimo, Volterrani, Maurizio, Ponikowski, Piotr, Jankowska, Ewa A, Chioncel, Ovidiu, Mcdonagh, Theresa A, Piepoli, Massimo F, Milicic, Davor, Thum, Thoma, Hill, Loreena, Abdelhamid, Magdy, Adamopoulos, Stamati, Belenkov, Yuri, Gal, Tuvia Ben, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antonio, Van Linthout, Sophia, Anker, Stefan D, Tocchetti, Carlo Gabriele, Lopatin, Yury, Lund, Lar, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Marku, and Rosano, Giuseppe M C

Subjects
Heart Failure, Certification, Europe, Humans, Societies, Medical, Cardiology, Quality of patient-centred, Heart failure, Medical and Health Sciences, Comprehensive educational programme, Medical, Quality of care centres, Clinical Medicine, Societies
Abstract

Heart failure (HF) is a devastating chronic and disabling disease with a wide variety of pharmaceutical and device treatment options which are becoming increasingly complex to implement. According to the Heart Failure Association (HFA) Atlas, a subspeciality resource aimed at sourcing contemporary data concerning the epidemiology and healthcare resources for HF, HF is prevalent in17.20 patients per1000 persons, accounting for 2671HFhospitalizations per million inhabitants annually in Europe.1HFpatients also suffer from a high prevalence of non-cardiac comorbidities, which adds complexity to their HF treatment and can negatively impact prognosis.2As a result, HF-related healthcare expenditure continues to rise, and healthcare organizations are becoming faced with the impossible challenge to provide the necessary financial and logistical support to this growing number of patients. In order to address these challenges, the HFA recently outlined the development of quality of care centres (QCC), in order to encourage multidisciplinary management of HF that will improve quality of care and survival.3However, there remains a significant unmet need to train sufficient multidisciplinary teams lead by HF specialists to take care of this expanding group of HF patients. In order to ensure that the next generation of medically-qualified HF specialists will receive high-quality training, this consensus statement of the HFA outlines the requirements for a European training and certification programme for such specialists. The primary goal of this comprehensive educational programme is to increase the quality of patient-centred care related to HF.

Published
2022
Full Text
View/download PDF

35. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Author

Núñez, Julio, primary, de la Espriella, Rafael, additional, Rossignol, Patrick, additional, Voors, Adriaan A., additional, Mullens, Wilfried, additional, Metra, Marco, additional, Chioncel, Ovidiu, additional, Januzzi, James L., additional, Mueller, Christian, additional, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, González, Arantxa, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Gal, Tuvia Ben, additional, Biegus, Jan, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Milicic, Davor, additional, Moura, Brenda, additional, Piepoli, Massimo F., additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayes‐Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

36. Abstract 12310: Benefits of Early Co-administration of Beta-blockers and Ivabradine in Patients Hospitalized Due to Worsening Heart Failure: Insights From a Prospective Pragmatic Study Within the Optimize Heart Failure Care Program

Author

Lopatin, Yury, Grebennikova, Anna, Sisakian, Hamayak, Hayrapetyan, Hamlet, Pagava, Zurab, Glezer, Maria, Chesnikova, Anna, Abdullaev, Timur, Dadashova, Gulnaz, Tarlovskaya, Ekaterina, Kurlianskaya, Alena, Koziolova, Natalia, Berkinbaev, Salim, Rakisheva, Amina, Voronkov, Leonid, Tseluyko, Vera, and Kipiani, Zviad

Published
2017

37. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter‐defibrillator for primary prevention?

Author

Abdelhamid, Magdy, primary, Rosano, Giuseppe, additional, Metra, Marco, additional, Adamopoulos, Stamatis, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Filippatos, Gerasimos, additional, Jankowska, Ewa A., additional, Lopatin, Yury, additional, Lund, Lars, additional, Milicic, Davor, additional, Moura, Brenda, additional, Ben Gal, Tuvia, additional, Ristic, Arsen, additional, Rakisheva, Amina, additional, Savarese, Gianluigi, additional, Mullens, Wilfried, additional, Piepoli, Massimo, additional, Bayes‐Genis, Antoni, additional, Thum, Thomas, additional, Anker, Stefan D., additional, Seferovic, Petar, additional, and Coats, Andrew J.S., additional

Published
2022
Full Text
View/download PDF

38. Cardiac Remodelling Part 1: From Cells and Tissues to Circulating Biomarkers:From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

González, Arantxa, Richards, A Mark, Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao‐Pires, Inês, Díez, Javier, Foo, Roger SY, Chan, Mark Yan Yee, Aimo, Alberto, Anene‐Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen‐Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew JS, and Bayes‐Genis, Antoni

Subjects
Tissue, Cells, Cardiology and Cardiovascular Medicine, Biomarkers, Remodeling
Abstract

Cardiac remodelling refers to changes in left ventricular (LV) structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leukocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g., proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and many biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of review paper on biomarkers of cardiac remodelling.

Published
2022
Full Text
View/download PDF

39. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)

Author

Glikson, Michael, Nielsen, Jens Cosedis, Kronborg, Mads Brix, Michowitz, Yoav, Auricchio, Angelo, Barbash, Israel Moshe, Barrabés, José A., Boriani, Giuseppe, Braunschweig, Frieder, Brignole, Michele, Burri, Haran, Coats, Andrew J. S., Deharo, Jean-Claude, Delgado, Victoria, Diller, Gerhard-Paul, Israel, Carsten W, Keren, Andre, Knops, Reinoud E., Kotecha, Dipak, Leclercq, Christophe, Merkely, Béla, Starck, Christoph, Thylén, Ingela, Tolosana, José Maria, Leyva, Francisco, Linde, Cecilia, Abdelhamid, Magdy, Aboyans, Victor, Arbelo, Elena, Asteggiano, Riccardo, Barón-Esquivias, Gonzalo, Bauersachs, Johann, Biffi, Mauro, Birgersdotter-Green, Ulrika, Bongiorni, Maria Grazia, Borger, Michael A, Čelutkienė, Jelena, Cikes, Maja, Daubert, Jean-Claude, Drossart, Inga, Ellenbogen, Kenneth, Elliott, Perry M, Fabritz, Larissa, Falk, Volkmar, Fauchier, Laurent, Fernández-Avilés, Francisco, Foldager, Dan, Gadler, Fredrik, De Vinuesa, Pastora Gallego Garcia, Gorenek, Bulent, Guerra, Jose M., Hermann Haugaa, Kristina, Hendriks, Jeroen, Kahan, Thomas, Katus, Hugo A, Konradi, Aleksandra, Koskinas, Konstantinos C, Law, Hannah, Lewis, Basil S, Linker, Nicholas John, Løchen, Maja-Lisa, Lumens, Joost, Mascherbauer, Julia, Mullens, Wilfried, Nagy, Klaudia Vivien, Prescott, Eva, Raatikainen, Pekka, Rakisheva, Amina, Reichlin, Tobias, Ricci, Renato Pietro, Shlyakhto, Evgeny, Sitges, Marta, Sousa-Uva, Miguel, Sutton, Richard, Suwalski, Piotr, Svendsen, Jesper Hastrup, Touyz, Rhian M, Van Gelder, Isabelle C, Vernooy, Kevin, Waltenberger, Johannes, Whinnett, Zachary, Witte, Klaus K., Glikson, Michael, Nielsen, Jens Cosedis, Kronborg, Mads Brix, Michowitz, Yoav, Auricchio, Angelo, Barbash, Israel Moshe, Barrabés, José A., Boriani, Giuseppe, Braunschweig, Frieder, Brignole, Michele, Burri, Haran, Coats, Andrew J. S., Deharo, Jean-Claude, Delgado, Victoria, Diller, Gerhard-Paul, Israel, Carsten W, Keren, Andre, Knops, Reinoud E., Kotecha, Dipak, Leclercq, Christophe, Merkely, Béla, Starck, Christoph, Thylén, Ingela, Tolosana, José Maria, Leyva, Francisco, Linde, Cecilia, Abdelhamid, Magdy, Aboyans, Victor, Arbelo, Elena, Asteggiano, Riccardo, Barón-Esquivias, Gonzalo, Bauersachs, Johann, Biffi, Mauro, Birgersdotter-Green, Ulrika, Bongiorni, Maria Grazia, Borger, Michael A, Čelutkienė, Jelena, Cikes, Maja, Daubert, Jean-Claude, Drossart, Inga, Ellenbogen, Kenneth, Elliott, Perry M, Fabritz, Larissa, Falk, Volkmar, Fauchier, Laurent, Fernández-Avilés, Francisco, Foldager, Dan, Gadler, Fredrik, De Vinuesa, Pastora Gallego Garcia, Gorenek, Bulent, Guerra, Jose M., Hermann Haugaa, Kristina, Hendriks, Jeroen, Kahan, Thomas, Katus, Hugo A, Konradi, Aleksandra, Koskinas, Konstantinos C, Law, Hannah, Lewis, Basil S, Linker, Nicholas John, Løchen, Maja-Lisa, Lumens, Joost, Mascherbauer, Julia, Mullens, Wilfried, Nagy, Klaudia Vivien, Prescott, Eva, Raatikainen, Pekka, Rakisheva, Amina, Reichlin, Tobias, Ricci, Renato Pietro, Shlyakhto, Evgeny, Sitges, Marta, Sousa-Uva, Miguel, Sutton, Richard, Suwalski, Piotr, Svendsen, Jesper Hastrup, Touyz, Rhian M, Van Gelder, Isabelle C, Vernooy, Kevin, Waltenberger, Johannes, Whinnett, Zachary, and Witte, Klaus K.

Published
2022

40. Congestion in heart failure:a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Author

Núñez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A, Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L, Mueller, Christian, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, González, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Ben Gal, Tuvia, Biegus, Jan, Cohen-Solal, Alain, Böhm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Núñez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A, Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L, Mueller, Christian, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, González, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Ben Gal, Tuvia, Biegus, Jan, Cohen-Solal, Alain, Böhm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F, Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni

Abstract

Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed.

Published
2022

41. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)

Author

Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M., Badagliacca, Roberto, Berger, Rolf M. F., Brida, Margarita, Carlsen, Jorn, Coats, Andrew J. S., Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S., Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G., Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M., Pepke-Zaba, Joanna, Quint, Jennifer K., Radegran, Goran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean-Luc, Noordegraaf, Anton Vonk, Delcroix, Marion, Rosenkranz, Stephan, Schwerzmann, Markus, Bush, Andy, Abdelhamid, Magdy, Aboyans, Victor, Arbustini, Eloisa, Asteggiano, Riccardo, Barbera, Joan-Albert, Beghetti, Maurice, Cikes, Maja, Condliffe, Robin, de Man, Frances, Falk, Volkmar, Fauchier, Laurent, Gaine, Sean, Galie, Nazzareno, Gin-Sing, Wendy, Granton, John, Grunig, Ekkehard, Hassoun, Paul M., Hellemons, Merel, Jaarsma, Tiny, Kjellstrom, Barbro, Klok, Frederikus A., Konradi, Aleksandra, Koskinas, Konstantinos C., Kotecha, Dipak, Lang, Irene, Lewis, Basil S., Linhart, Ales, Lip, Gregory Y. H., Lochen, Maja-Lisa, Mathioudakis, Alexander G., Mindham, Richard, Moledina, Shahin, Naeije, Robert, Nielsen, Jens Cosedis, Olschewski, Horst, Opitz, Isabelle, Petersen, Steffen E., Prescott, Eva, Rakisheva, Amina, Reis, Abilio, Ristic, Arsen D., Roche, Nicolas, Rodrigues, Rita, Selton-Suty, Christine, Souza, Rogerio, Swift, Andrew J., Touyz, Rhian M., Ulrich, Silvia, Wilkins, Martin R., Wort, Stephen John, Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M., Badagliacca, Roberto, Berger, Rolf M. F., Brida, Margarita, Carlsen, Jorn, Coats, Andrew J. S., Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S., Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G., Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M., Pepke-Zaba, Joanna, Quint, Jennifer K., Radegran, Goran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean-Luc, Noordegraaf, Anton Vonk, Delcroix, Marion, Rosenkranz, Stephan, Schwerzmann, Markus, Bush, Andy, Abdelhamid, Magdy, Aboyans, Victor, Arbustini, Eloisa, Asteggiano, Riccardo, Barbera, Joan-Albert, Beghetti, Maurice, Cikes, Maja, Condliffe, Robin, de Man, Frances, Falk, Volkmar, Fauchier, Laurent, Gaine, Sean, Galie, Nazzareno, Gin-Sing, Wendy, Granton, John, Grunig, Ekkehard, Hassoun, Paul M., Hellemons, Merel, Jaarsma, Tiny, Kjellstrom, Barbro, Klok, Frederikus A., Konradi, Aleksandra, Koskinas, Konstantinos C., Kotecha, Dipak, Lang, Irene, Lewis, Basil S., Linhart, Ales, Lip, Gregory Y. H., Lochen, Maja-Lisa, Mathioudakis, Alexander G., Mindham, Richard, Moledina, Shahin, Naeije, Robert, Nielsen, Jens Cosedis, Olschewski, Horst, Opitz, Isabelle, Petersen, Steffen E., Prescott, Eva, Rakisheva, Amina, Reis, Abilio, Ristic, Arsen D., Roche, Nicolas, Rodrigues, Rita, Selton-Suty, Christine, Souza, Rogerio, Swift, Andrew J., Touyz, Rhian M., Ulrich, Silvia, Wilkins, Martin R., and Wort, Stephen John

Published
2022

42. 2021 ESC/EACTS Guidelines for the management of valvular heart disease

Author

Vahanian, Alec, Beyersdorf, Friedhelm, Praz, Fabien, Milojevic, Milan, Baldus, Stephan, Bauersachs, Johann, Capodanno, Davide, Conradi, Lenard, De Bonis, Michele, De Paulis, Ruggero, Delgado, Victoria, Freemantle, Nick, Gilard, Martine, Haugaa, Kristina H., Jeppsson, Anders, Jüni, Peter, Pierard, Luc, Prendergast, Bernard D., Sadaba, J. Rafael, Tribouilloy, Christophe, Wojakowski, Wojtek, Neumann, Franz Josef, Myers, Patrick, Abdelhamid, Magdy, Achenbach, Stephan, Asteggiano, Riccardo, Barili, Fabio, Borger, Michael A., Carrel, Thierry, Collet, Jean Philippe, Foldager, Dan, Habib, Gilbert, Hassager, Christian, Irs, Alar, Iung, Bernard, Jahangiri, Marjan, Katus, Hugo A., Koskinas, Konstantinos C., Massberg, Steffen, Mueller, Christian E., Nielsen, Jens Cosedis, Pibarot, Philippe, Rakisheva, Amina, Roffi, Marco, Rubboli, Andrea, Shlyakhto, Evgeny, Siepe, Matthias, Sitges, Marta, Sondergaard, Lars, Prescott, Eva, Vahanian, Alec, Beyersdorf, Friedhelm, Praz, Fabien, Milojevic, Milan, Baldus, Stephan, Bauersachs, Johann, Capodanno, Davide, Conradi, Lenard, De Bonis, Michele, De Paulis, Ruggero, Delgado, Victoria, Freemantle, Nick, Gilard, Martine, Haugaa, Kristina H., Jeppsson, Anders, Jüni, Peter, Pierard, Luc, Prendergast, Bernard D., Sadaba, J. Rafael, Tribouilloy, Christophe, Wojakowski, Wojtek, Neumann, Franz Josef, Myers, Patrick, Abdelhamid, Magdy, Achenbach, Stephan, Asteggiano, Riccardo, Barili, Fabio, Borger, Michael A., Carrel, Thierry, Collet, Jean Philippe, Foldager, Dan, Habib, Gilbert, Hassager, Christian, Irs, Alar, Iung, Bernard, Jahangiri, Marjan, Katus, Hugo A., Koskinas, Konstantinos C., Massberg, Steffen, Mueller, Christian E., Nielsen, Jens Cosedis, Pibarot, Philippe, Rakisheva, Amina, Roffi, Marco, Rubboli, Andrea, Shlyakhto, Evgeny, Siepe, Matthias, Sitges, Marta, Sondergaard, Lars, and Prescott, Eva

Published
2022

43. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings:A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Ben Gal, Tuvia, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, Bayes-Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, González, Arantxa, Barison, Andrea, Lupón, Josep, Delgado, Victoria, Richards, A Mark, de Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Ben Gal, Tuvia, Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, and Bayes-Genis, Antoni

Abstract

In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.

Published
2022

44. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Author

Nunez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A., Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L., Mueller, Christian, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Gonzalez, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Boehm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F., Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Nunez, Julio, de la Espriella, Rafael, Rossignol, Patrick, Voors, Adriaan A., Mullens, Wilfried, Metra, Marco, Chioncel, Ovidiu, Januzzi, James L., Mueller, Christian, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Gonzalez, Arantxa, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Gal, Tuvia Ben, Biegus, Jan, Cohen-Solal, Alain, Boehm, Michael, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Milicic, Davor, Moura, Brenda, Piepoli, Massimo F., Ponikowski, Piotr, Rakisheva, Amina, Ristic, Arsen, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni

Abstract

Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed., Funding Agencies|Ministry of Economy and Competitiveness; Instituto Carlos III [PI20/00392]; CIBER Cardiovascular [16/11/00420, 16/11/00403]

Published
2022
Full Text
View/download PDF

45. Cardiac remodelling – Part 1:From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

González, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S.Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J.S., Bayés-Genís, Antoni, González, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao-Pires, Inês, Díez, Javier, Foo, Roger S.Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristić, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J.S., and Bayés-Genís, Antoni

Abstract

Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling.

Published
2022

46. Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Gonzalez, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Boehm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Bayes-Genis, Antoni, Gonzalez, Arantxa, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Y., Aimo, Alberto, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Boehm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep S., Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., and Bayes-Genis, Antoni

Abstract

Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling., Funding Agencies|Spanish Ministry of Science, Innovation and Universities Institute of Health Carlos III (ISCIII) [PI18/01469, PI21/00946, CB16/11/00403, CB16/11/00483]; European Regional Development FundsEuropean Commission; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [2019-848109-2]; European Research CouncilEuropean Research Council (ERC)European Commission [ERC CoG 818715]; ERC-PoC Megfib; National Medical Research Council of Singapore (NMRC)National Medical Research Council, Singapore [NMRC/STaR/0022/2014, MOH-000280]; Health Research Council of New ZealandHealth Research Council of New Zealand [02/152, 08/070, 11/1070]; National Heart Foundation of New Zealand; New Zealand Lotteries Grant Board; Foundation for Research, Science and TechnologyNew Zealand Foundation for Research, Science and Technology; Christchurch Heart Institute Trust; Netherlands Heart FoundationNetherlands Heart Foundation [2017-21, 2017-11, 2018-30, 2020B005]; leDucq FoundationLeducq Foundation; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [KFO311, TRR267, TTR 219, TRR 1470]; Karolinska Institutet, the Swedish Research CouncilSwedish Research Council [523-2014-2336]; Swedish Heart Lung FoundationSwedish Heart-Lung Foundation [20150557, 20190310]; Stockholm County CouncilStockholm County Council [20170112, 20190525]

Published
2022
Full Text
View/download PDF

47. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Aimo, Alberto, Vergaro, Giuseppe, Gonzalez, Arantxa, Barison, Andrea, Lupon, Josep, Delgado, Victoria, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Bohm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, Bayes-Genis, Antoni, Aimo, Alberto, Vergaro, Giuseppe, Gonzalez, Arantxa, Barison, Andrea, Lupon, Josep, Delgado, Victoria, Richards, A. Mark, de Boer, Rudolf A., Thum, Thomas, Arfsten, Henrike, Hulsmann, Martin, Falcao-Pires, Ines, Diez, Javier, Foo, Roger S. Y., Chan, Mark Yan Yee, Anene-Nzelu, Chukwuemeka G., Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D., Belenkov, Yuri, Gal, Tuvia B., Cohen-Solal, Alain, Bohm, Michael, Chioncel, Ovidiu, Jankowska, Ewa A., Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L., Jhund, Pardeep, Lopatin, Yuri, Lund, Lars H., Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Nunez, Julio, Piepoli, Massimo F., Rakisheva, Amina, Ristic, Arsen D., Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G., van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew J. S., Emdin, Michele, and Bayes-Genis, Antoni

Abstract

In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.

Published
2022
Full Text
View/download PDF

48. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology

Author

Verplegingswetenschap, Circulatory Health, Mullens, Wilfried, Coats, Andrew, Seferovic, Petar, Metra, Marco, Mebazaa, Alexandre, Ruschitzka, Frank, Filippatos, Gerasimos, Volterrani, Maurizio, Ponikowski, Piotr, Jankowska, Ewa A, Chioncel, Ovidiu, McDonagh, Theresa A, Piepoli, Massimo F, Milicic, Davor, Thum, Thomas, Hill, Loreena, Abdelhamid, Magdy, Adamopoulos, Stamatis, Belenkov, Yuri, Ben Gal, Tuvia, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antonio, Van Linthout, Sophie, Anker, Stefan D, Tocchetti, Carlo Gabriele, Lopatin, Yury, Lund, Lars, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Markus, Rosano, Giuseppe M C, Verplegingswetenschap, Circulatory Health, Mullens, Wilfried, Coats, Andrew, Seferovic, Petar, Metra, Marco, Mebazaa, Alexandre, Ruschitzka, Frank, Filippatos, Gerasimos, Volterrani, Maurizio, Ponikowski, Piotr, Jankowska, Ewa A, Chioncel, Ovidiu, McDonagh, Theresa A, Piepoli, Massimo F, Milicic, Davor, Thum, Thomas, Hill, Loreena, Abdelhamid, Magdy, Adamopoulos, Stamatis, Belenkov, Yuri, Ben Gal, Tuvia, Böhm, Michael, Cohen-Solal, Alain, Gustafsson, Finn, Jaarsma, Tiny, Moura, Brenda, Rakisheva, Amina, Ristic, Arsen, Bayes-Genis, Antonio, Van Linthout, Sophie, Anker, Stefan D, Tocchetti, Carlo Gabriele, Lopatin, Yury, Lund, Lars, Savarese, Gianluigi, Čelutkienė, Jelena, Cowie, Martin, Lambrinou, Ekaterini, Ray, Robin, Lainscak, Mitja, Skouri, Hadi, Wallner, Markus, and Rosano, Giuseppe M C

Published
2022

49. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Aimo, Alberto, primary, Vergaro, Giuseppe, additional, González, Arantxa, additional, Barison, Andrea, additional, Lupón, Josep, additional, Delgado, Victoria, additional, Richards, A Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Yan Yee, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, Emdin, Michele, additional, and Bayes‐Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

50. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

González, Arantxa, primary, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Y., additional, Aimo, Alberto, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Delgado, Victoria, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayés‐Genís, Antoni, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results